CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Revenue:
Genetic testing	$ 324,837	$ 483,214	$ 672,737	$ 903,547
Other	51,214	45,381	106,526	112,614
Total revenue	376,051	528,595	779,263	1,016,161
Cost of revenue	331,555	361,746	662,596	756,517
Gross profit	44,496	166,849	116,667	259,644
Operating expenses:
Research and development	384,538	215,519	567,068	424,696
Selling, general and administrative	1,655,226	1,506,057	3,218,017	3,032,663
Amortization of intangibles	19,414	23,525	38,828	47,050
Total operating expenses	2,059,178	1,745,101	3,823,913	3,504,409
Loss from operations	(2,014,682)	(1,578,252)	(3,707,246)	(3,244,765)
Other income (expense):
Interest income	0	1,605	222	3,599
Interest expense	(152,104)	0	(302,957)	0
Total other income (expense)	(152,104)	1,605	(302,735)	3,599
Loss before income taxes	(2,166,786)	(1,576,647)	(4,009,981)	(3,241,166)
Benefit for income taxes	0	0	0	0
Net loss	$ (2,166,786)	$ (1,576,647)	$ (4,009,981)	$ (3,241,166)
Basic and diluted net loss per common share (in dollars per share)	$ (0.01)	$ (0.01)	$ (0.02)	$ (0.03)
Weighted average common shares outstanding, basic and diluted (in shares)	172,786,907	122,516,317	172,762,366	122,499,091